linjc16/ctgov huggingface dataset:
The Effect of Vitamin A With and Without Zinc and Multivitamin Supplementation on Malaria Morbidity in Ghanaian Children

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to determine the effect of combining vitamin A (VA), zinc (Z) and multivitamins (MV- A, B1, B2, B6, B12, C, D and E) on malaria morbidity

Detailed Description
-----------------
A total of 542 children aged between 6-59 months received either: (i) VA (control) or (ii) VA & Z (VAZ) or (iii) VA, Z & MV (VAZM). VA was delivered as a single dose while MV and Z were delivered daily. Malaria cases were managed by community health workers, who used rapid diagnostic test to confirm infection prior to treatment.

Official Title
-----------------
The Effect of Vitamin A With and Without Zinc and Multivitamin Supplementation on Malaria Morbidity in Ghanaian Children

Conditions
-----------------
Malaria

Intervention / Treatment
-----------------
* Dietary Supplement: Vitamin A
* Dietary Supplement: Vitamin A and ZInc
* Dietary Supplement: Vitamin A , Zinc and Multivitamin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: under 5years will stay in the community for 10years Exclusion Criteria: chronic diseases
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Vitamin A<br>A single dose of 20,000IU Vitamin A for the whole study period | Dietary Supplement: Vitamin A<br>* Vitamin A supplements<br>* Other names: VA;|
| Active Comparator: Vitamin A and zinc<br>A single dose of 20,000IU Vitamin A and 10mg of elemental zinc each day for 5 months | Dietary Supplement: Vitamin A and ZInc<br>* Combination of vitamin A and zinc supplements<br>* Other names: VAZ;|
| Active Comparator: Vitamin A , Zinc and Multivitamin<br>A single dose of 20,000IU Vitamin A , 10mg of elemental zinc each day and 0.5ml/kg multivitamin syrup for 5 months | Dietary Supplement: Vitamin A , Zinc and Multivitamin<br>* Combination of vitamin A, zinc and multivitamins<br>* Other names: VAZM;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of clinical malaria attacks | While taking the supplement, malaria incidence will be measured | Baseline and every month up to six months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of diarrhea attacks | While taking the supplement, diarrhea incidence will be measured | Every month up to six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
malaria, vitamin A, Zinc, Multivitamin
Retrospective Evaluation of the Clinical Results Obtained in Patients With Acute Lymphoblastic Leukemia Treated at the San Giovanni Battista Hospital.

Study Overview
=================
Brief Summary
-----------------
This study provides for the collection of a series composed by patients with newly diagnosed of acute lymphoblastic leukemia in the period 1999-2011. This collection is carried out with retrospective investigation, through the review of paper and electronic records and data cards in large part already collected as part of study protocols GIMEMA or BFM or NILG approved by the Ethics Committee of Hospital. The purpose of data collection is to check with retrospective predictability of classical risk factors in relation to disease response, and overall survival of the event-free survival, to estimate the cumulative incidence of competitive events such as the emergence of disease, acute and chronic transplant, the transplant-related mortality and relapse of disease.

Official Title
-----------------
Retrospective Evaluation of the Clinical Results Obtained in Patients With Acute Lymphoblastic Leukemia Treated at the San Giovanni Battista Hospital.

Conditions
-----------------
Disease: Acute Lymphoblastic Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Patients with newly diagnosed of acute lymphoblastic leukemia enrolled from 1999 to 2011 at the Division of Hematology, Molinette University Hospital and candidates for therapeutic approach with curative intent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 1 year | 
| Event-free survival |  | 1 year |
The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema

Study Overview
=================
Brief Summary
-----------------
after advent of RD photoreceptor degeneration Occurred. This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened . Process of degeneration begins from first hours of RD establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years . How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researches. In the study investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study.

Official Title
-----------------
The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema

Conditions
-----------------
Refractory Diabetic Macular Edema

Intervention / Treatment
-----------------
* Drug: injection of bevacizumab and erythropoietin
* Drug: injection of bevacizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with refractory diabetic macular edema at least one month after third injection Exclusion Criteria: previous vitreoretinal surgery previous glaucoma surgery glaucomatous patient open heart surgery active proliferative diabetic retinopathy one eye patients vitreous hemorrhage
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: intravitreal injection of bevacizumab and erythropoietin<br>erythropoietin: | Drug: injection of bevacizumab and erythropoietin<br>* injection of bevacizumab and erythropoietin<br>|
| Active Comparator: intravitreal injection of bevacizumab<br>bevacizumab:1.25 mg | Drug: injection of bevacizumab<br>* under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| best corrected visual acuity | Snellen chart | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Optical coherence tomography | Optical coherence tomography | 1 month |
Role of MR Spectroscopy in Brain Tumors

Study Overview
=================
Brief Summary
-----------------
In order to come as close as possible to the correct diagnosis of CNS tumors, MRI is the long-standing accepted method of choice that can in some cases be supported by the use of CT to demonstrate calcification or bone destruction. In individual cases MRI spectroscopy can be helpful for the differentiation between neoplasms and inflammatory lesions or surveillance of tumor therapy, just as perfusion

Detailed Description
-----------------
Proton magnetic resonance spectroscopy (H-MRS) may be helpful in suggesting tumor histology and tumor grade and may better define tumor extension and the ideal site for biopsy compared with conventional magnetic resonance (MR) imaging. A multifunctional approach with diffusion-weighted imaging, perfusion-weighted imaging, and permeability maps, along with H-MRS, may enhance the accuracy of the diagnosis and characterization of brain tumors and estimation of therapeutic response. Integration of advanced imaging techniques with conventional MR imaging and the clinical history help to improve the accuracy, sensitivity, and specificity in differentiating tumors and nonneoplastic lesions.

Official Title
-----------------
Role of Magnetic Resonance Spectroscopy in Differentiating Brain Tumors

Conditions
-----------------
Brain Neoplasms

Intervention / Treatment
-----------------
* Device: MRI Spectroscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with space-occupying lesions Exclusion Criteria: Post operative cases Non-neoplastic nature

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: MRI Spectroscopy|Patient with brain SOL underwent MRI Spectroscopy to be compared with later pathology|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of MRS findings with the pathology of the specimens | Analysis of the MRS metabolites peaks and integral and test if they can differentiate the grades of brain tumors | Baseline |
Acceptability Study of Sensor in Elderly People's House Living Alone (Fragility Box)

Study Overview
=================
Brief Summary
-----------------
The Fragility box is a project lead by Mines de Saint-Etienne, Gérontopôle Auvergne-Rhône-Alpes (AURA) and Eovi Mcd Mutually to prevent autonomy loss in the elderly dwelling population. With non-intrusive sensors installed in their residence, it is possible to monitor and forecast the frail state of elderly people living alone. The current study focuses on the technical feasibility of the project and the acceptability of these types of devices within the elderly's home. About ten participants have volunteered to be a part of this study. Therefore, they had the sensors installed at their home for a 12 months duration. A qualitative study with focus groups and individual interviews are carried out to evaluate the project: user satisfaction, expectations, and fears.

Detailed Description
-----------------
This research tend to study the acceptability of captors which can measure the evolution of autonomy of older 65 people.

Official Title
-----------------
Acceptability Study of Sensor in Elderly People's House Living Alone

Conditions
-----------------
Aging

Intervention / Treatment
-----------------
* Other: Focus groups
* Other: Individual interviews


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People living alone Autonomous person Exclusion Criteria: Person with a neurological disease Person under guardianship or curatorship

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Older 65 people<br>Older 65 people who live alone in their house will be included. They will have focus groups and Individual interviews. | Other: Focus groups<br>* discussion between participants about representations of health, dependance, fragility, and new technologies<br>Other: Individual interviews<br>* Discussion between the searcher and the participant about representations of captors, discretion of captors, wish about feed-backs of captors<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis representations of health/fragility and new technologies | Measured by focus groups results. | Months:6 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis Representations of health and frailties ; and new technologies Acceptability of sensors | Measured by individual interviews results. | Months:6 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sensors, acceptability, qualitative study, autonomous, elderly people, prevention, Autonomy loss
Polk COVID-19 and Flu Response

Study Overview
=================
Brief Summary
-----------------
Study Objectives: To perform COVID-19 diagnostic and serologic testing on emergency medical personnel in Polk County to determine: COVID-19 prevalence Rate of convalesced personnel (+antibodies) Rate of asymptomatic carriers

Detailed Description
-----------------
This observational study involves a community wide program offering free COVID-19 testing to county front line workers, including EMS personnel, board of county commissioners and sheriffs' office personnel. These personnel will also be asked to fill out a survey that asks about their medical history and which of any symptoms they have experienced in the prior three weeks. The survey is voluntary and written informed consent is obtained . EMS personnel can still get the free testing even if they do not want to fill out the survey. The primary objective of the study is to describe the prevalence of COVID-19 antigen and IgM and IgG markers amongst our county/EMS workers. The secondary objective is to describe whether the antigen/antibody markers are significantly correlated to the presence of a set of symptoms in the prior 3 weeks, and/or to the baseline demographics such as age, sex, and presence of co-morbidities.

Official Title
-----------------
County-wide Emergency Personnel Assessment of COVID-19 and Influenza Status

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Diagnostic Test: COVID-19 antigen and antibody tests, and influenza rapid test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Polk County (FL) emergency personnel including EMS, Fire Rescue, Board of County Commissioners, and Sheriff's office Exclusion Criteria: Age < 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: COVID-19 antigen and antibody tests, and influenza rapid test|Study volunteers will be offered free COVID-19 and influenza testing and the opportunity to complete an electronic survey about any symptoms.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of COVID-19 amongst county emergency personnel | To assess the prevalence of COVID-19 amongst county emergency personnel | May-December 2020 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of common COVID-19 symptoms with result of COVID-19 test | To correlate common COVID-19 symptoms with result of COVID-19 test | May-December 2020 | 
| Co-existence of influenza and COVID-19 positive test results | Co-existence of influenza and COVID-19 positive test results with or without symptoms | May-December 2020 |
The Relationship Between Structure and Visual Function in Myopia Foveoschisis

Study Overview
=================
Brief Summary
-----------------
Macular foveoschisis (MF) is a common complication of pathological myopia, which is characterized by choroid-retinal degeneration and vision impairment. Although pars plana vitrectomy (PPV) is the primary method for MF treatment, there is still a large proportion of recurrent MF due to the extremely long global axial length and posterior staphyloma. Macular buckling (MB) surgery aims at counteracting the traction exerted by the posterior staphyloma, and has been proven an effective method for treating MF. Optical Coherence Tomography (OCT) is widely used for the structural analysis of MF. Multifocol electroretinogram (mfERG) is an objective examination for visual evaluation. To our knowledge, there is a lack of data on the comprehensive visual function evaluations of MF patients associated with OCT findings. Our clinical trial aims to provide the structural and functional relationship in MF patients undergoing MB surgery, and find out potential factors to determine the visual prognosis.

Official Title
-----------------
Correlation of Structural and Visual Function Changes in Myopia Foveoschisis Patients Undergoing Macular Buckle Surgery

Conditions
-----------------
High Myopia

Intervention / Treatment
-----------------
* Procedure: macular buckling surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: axial length ≥ 26.5 mm or refractive error (spherical equivalent) ≥ 8.0 diopter; macular foveoschisis that requires surgical intervention. Exclusion Criteria: ocular trauma or surgery history; glaucoma, diabetic retinopathy; intraocular active hemorrhage or inflammation; unable to coordinate the OCT, mfERG, or other ophthalmological examinations.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MF-MB<br>Consecutive participants with high myopic foveoschisis are scheduled to macular buckling (MB) surgery. | Procedure: macular buckling surgery<br>* Participants with high myopia foveoschisis are scheduled to macular buckling (MB) surgery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change from baseline OCT at 6 months |  | 6 month postoperatively | 
| change from multifocal ERG at 6 months |  | 6 month postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change from Best-corrected visual acuity (BCVA) at 6 months |  | 6 month postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
high myopia, myopia foveoschisis, macular buckling
Decision Aids for Tamoxifen Treatment in Breast Cancer Patients

Study Overview
=================
Brief Summary
-----------------
This is an educational intervention study for breast cancer patients who undergo tamoxifen treatment. The purpose of the study is to assess the impact of decision aids (DA) on the patients' decision-making process, compliance on drug, and knowledge regarding tamoxifen treatment. Patients will randomly assign to DA group or conventional group. Both groups will have baseline questionnaire surveys before starting tamoxifen treatment, and 4 weeks later follow-up questionnaire surveys.

Official Title
-----------------
Utilization of Decision Aids for Tamoxifen Treatment in Breast Cancer Patients: A Randomized Controlled Trial.

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Behavioral: Decision aids (tamoxifen-related educational materials in brochure or mobile app)
* Drug: tamoxifen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Breast cancer patients who are recommended to undergo tamoxifen treatment in National Cancer Center, Korea - Age at least 18 years and more Exclusion Criteria: Age under 18 years Inability to read or speak Korean Disagree to provide a written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Decision aids<br> | Behavioral: Decision aids (tamoxifen-related educational materials in brochure or mobile app)<br>* Decision aids (tamoxifen-related educational materials in brochure or mobile app)<br>Drug: tamoxifen<br> <br> |
| No Intervention: usual care<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Knowledge of Tamoxifen Scale |  | baseline, 4weeks later | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decisional Conflict Scale | Assess the decisional conflict regarding tamoxifen treatment | baseline, 4weeks later | 
| Satisfaction with Decision Questionnaire | Assess the satisfaction with decision to undergo tamoxifen treatment | baseline, 4weeks later | 
| EORTC QLQ-C30 Questionnaire | Assess the quality of life before and during tamoxfen treatment | baseline, 4weeks later | 
| EQ-5D Questionnaire | Assess the quality of life before and during tamoxfen treatment | baseline, 4weeks later | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast Neoplasms, Tamoxifen, Decision Aids